From positive late-stage trial results and FDA approvals to increased stake by notable asset management companies, Regeneron Pharmaceuticals (REGN) has had significant developments recently. The company's stock has seen movement due to results like the EMPOWER-Lung 3 trial and positive Phase 3 results for Cemdisiran and Garetosmab trials. Financial results for Q3 2025 are set to be released on October 28, 2025. Several investment firms, including Mirae Asset Global and Greenwood Capital Associates, have increased their stake in REGN. There has been a decrease in stock holdings by firms like Truist Financial Corp and Robeco Institutional Asset Management. Analysts maintain a buy rating for REGN with targets ranging from $640 to $815. Other key events include the FDA's approval of linvoseltamab for multiple myeloma and the label extension for cholesterol drug Evkeeza. However, not everything is positive as there are concerns over a court setback on EYLEA and regulatory concerns.
Regeneron Pharmaceuticals REGN News Analytics from Sat, 10 May 2025 07:00:00 GMT to Sat, 04 Oct 2025 18:30:06 GMT -
Rating 5
- Innovation 8
- Rumor 3
